MTI Profile: US FDA's Second-In-Command Has Her Eye On A Tech-Forward Future

As principal deputy commissioner of the FDA, Amy Abernethy is focused on developing overarching policies that affect all its product centers. But perhaps what will stand as her legacy is her work to develop a data-centered strategy to improve how the agency reviews products and ensures their long-term safety and efficacy.

FDA Deputy Commissioner Amy Abernathy speaking at Reagan-Udall Foundation for FDA.(
As the second-in-command at the US FDA, Amy Abernethy is also tasked with developing the agency's technology needs • Source: Ferdous Al-Faruque

More from Leadership

More from Medtech Insight